Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gallium Ga-68 gozetotide (Novartis)
- Development stage
- Approved
- Lead developer
- Telix Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Gallium Ga-68 gozetotide is a radiopharmaceutical agent used for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. It combines the peptidomimetic Glu-NH-CO-NH-Lys(Ahx)-HBED-CC with the radionuclide 68Ga, enabling specific imaging of tumor cells expressing PSMA. The compound binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress this protein. Gallium-68 is a β+ emitting radionuclide that allows for PET imaging. It was approved by the FDA in December 2020 as the first molecular-targeted drug for PET imaging of PSMA-positive lesions in men with prostate cancer.
- Brand names
- IlluccixLocametzProstamedix
- Other names
- Gallium (68Ga) gozetotideGallium Ga-68 gozetotideGlu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))Glu-NH-CO-NH-Lys-(Ahx)-(68Ga(HBED-CC))PSMA-HBED-CC Ga-68
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on gallium Ga-68 gozetotide (Novartis).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gallium Ga-68 gozetotide (Novartis).